The goal of this study is to create a national network to study individuals at-risk for developing Rheumatoid Arthritis. This will be done through two objectives Objective #1) Establish the infrastructure to identify and follow antibodies to citrullinated protein antigens (ACPA) positive individuals who have been identified through routine care at rheumatology clinical practices or previously e...
To evaluate the safety and tolerability of benralizumab
The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to < 6 mg/dL for at least 80% of the time.
The goal of the Accelerating Medicines Partnership (AMP) research study is to better understand the molecular and cellular characteristics of Rheumatoid Arthritis (RA) to help develop better therapies for people with RA.
To evaluate the efficacy of GS-5718 versus placebo-to-match (PTM) in reducing skin disease activity for participants with CLE with or without systemic lupus erythematosus. To evaluate the efficacy of GS-5718 versus PTM in reducing skin disease activity for participants with CLE with or without SLE. To evaluate the safety and tolerability of GS-5178 in participants with CLE with or without SLE.
For Period 1, the primary objective is to evaluate the efficacy and safety of upadacitinib and adalimumab, in adult subjects on background MTX, following an inadequate response or intolerance to a single TNFi. For Period 2, the objective is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib and adalimumab in subjects who have completed Period 1.
In this study, we plan to learn about the causes of rheumatoid arthritis (RA) and about lung disease in RA. RA is an autoimmune disease that can cause arthritis, and in some people, RA can also be related to lung disease called ‘interstitial lung disease’ (or ILD).
To evaluate the safety and effectiveness of the Spinal Kinetics M6-C™ artificial cervical disc in patients with contiguous twolevel symptomatic cervical radiculopathy with or without cord compression.
The purpose of this research study is to learn more about how CBD may reduce chronic pain and pain medication use.
Use of blood flow restriction cuffs in post surgical hip patients.
To learn more about lung disease and risk of lung disease in early RA.
This study involves chimeric antigen receptor (CAR) T cell therapy, which is a relatively new therapeutic approach that uses a patient's own immune cells to treat their disease. In autoimmune diseases such as rheumatoid arthritis (RA), certain parts of the immune system are overactive, leading to inflammation. A subtype of immune cells, called regulatory T cells (Tregs), normally help to reduce ...
The primary objective of the current study is to validate the performance of the current ASAS classification criteria in a prospective, combined cohort of patients presenting with undiagnosed current back pain.
This study is to evaluate the optimal postoperative analgesia modality (patient controlled analgesia,paravertebral nerve block, and intercostal nerve cryoablation) after minimally invasive repair of pectus excavatum (MIRPE) using a randomized control trial.
The primary objective of this study is to demonstrate efficacy of BIIB059 compared with placebo in participants with active systemic lupus erythematosus (SLE), who are receiving background lupus standard of care (SOC) therapy in reducing disease activity.
This study wants to learn about how total joint replacements affect the lives and physical abilities of children and young adults as they grow older.
To fully characterize safety and efficacy when the coflex® device is used in the intended subject population under the actual conditions of use”
To longitudinally study individuals at risk for spondyloarthritis and spondyloarthritis associated diseases.
We want to learn how to help teens with migraine live a better life!
To test CAR T cell therapy (a type of therapy made from one's own immune cells) for refractory lupus nephritis
Primary objective is to evaluate the effectiveness of cenerimod 4mg at reducing disease activity compared to placebo. The secondary objective is to evaluate the effect of cenerimod 4mg to control the disease compared to placebo. The safety objective is to evaluate the safety and tolerability of cenerimod 4mg.
